Research & Development
OUR APPROACH TO R&D
Our pharmaceutical research and development focus is on novel immunobiological drugs and therapies, initially concentrated on vaccine development and their market access for Russia and Eurasia. Moving forward, we intend to expand our pipeline by incorporating other novel immunobiological drugs and vaccines, oncology products, and products based on the latest mRNA technology platform, extending our reach further afield across select markets in Africa and Asia.
Our R&D approach encompasses:
• Epidemiological statistics and pharmacoeconomic analysis
• Scanning the global R&D landscape for available technology platforms and IP
• Non-clinical and clinical development pathways in target markets
• Diligent safety and efficacy profiling of drug candidates for licensing
• Local studies for regulatory approval
OUR FUTURE ROADMAP

CLINICAL TRIALS (PUBLICATIONS ARCHIVE)
All our vaccines are in-licensed from industry pioneers who have undertaken a comprehensive characterization, pre-clinical and clinical development program and have successfully marketed this in several countries worldwide. Furthermore, we have conducted rigorous due diligence of the product and have undertaken additional toxicology studies in rodents and primates, plus clinical development
H
in adults and children in the Russian federation to establish safety and efficacy in accordance with the requirements of state regulatory agencies and Eurasian harmonized protocols. We also pursue long term post-marketing surveillance studies on all of our products in the course of their commercialization life-cycle.
All our vaccines are in-licensed from industry pioneers who have undertaken a comprehensive characterization, pre-clinical and clinical development program and have successfully marketed this in several countries worldwide. Furthermore, we have conducted rigorous due diligence of the product and have undertaken additional toxicology studies in rodents and primates, plus clinical development in adults and children in the Russian federation to establish safety and efficacy in accordance with the requirements of state regulatory agencies and Eurasian harmonized protocols. We also pursue long term post-marketing surveillance studies on all of our products in the course of their commercialization life-cycle.
A. ROTAVIRUS VACCINE
– https://www.sabin.org/sites/sabin.org/files/sajjad_desai.pdf
– https://www.nejm.org/doi/pdf/10.1056/NEJMoa1609462
– https://clinicaltrials.gov/ct2/show/NCT02145000
– https://www.clinicaltrials.gov/ct2/show/NCT02133690
– https://www.path.org/media-center/serum-institutes-vaccine-demonstrates-significant-efficacy-against-severe-rotavirus-gastroenteritis/
– https://health.economictimes.indiatimes.com/news/pharma/serums-rotavirus-vaccine-shows-significant-efficacy-gets-govt-order-for-3-8-mn-doses/60841496
B. VARICELLA VACCINE
– http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=12388&EncHid=&userName=CTRI/2015/07/006059
– https://trialsearch.who.int/?TrialID=CTRI/2015/07/006059
C. HPV VACCINE
– http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=17680&EncHid=&userName=CTRI/2017/02/007785
– https://www.kemhrcvadu.org/index.php/projects/ongoing-projects/14-sample-data-articles/187-a-phase-ii-iii-partially-double-blindrandomized-active-controlled-multicentric-study-to-assess-the-immunogenicity-and-safety-of-siipl-s-qhpv-vaccine
– http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=26674&EncHid=&userName=ctri
D. MENINGOCOCCAL VACCINE
– https://clinicaltrials.gov/ct2/history/NCT03295318?A=4&B=5&C=Side-by-Side#StudyPageTop
– https://clinicaltrials.gov/ct2/history/NCT03295318?A=5&B=6&C=Side-by-Side#StudyPageTop
– https://www.nejm.org/doi/10.1056/NEJMoa2013615?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed
– https://clinicaltrials.gov/ct2/show/results/NCT03295318?view=results
REACHING NEW HEIGHTS TOGETHER
OPPORTUNITIES TO COLLABORATE
A
We firmly believe ‘true synergy is not about reinventing the wheel; instead, it relies on combining strengths with valued partners who are the best in their respective fields’. If our products or technologies are of interest for your local markets, or for accelerating market access within Russia and CIS, we would love to explore with you in further detail. Please reach out to us at info@pharmaid.com
We look forward to hearing your ideas and providing you with any additional information that you require.
SOME WAYS WE CAN WORK TOGETHER :
